Navigation Links
North Shore-LIJ Offering New Radium Treatment for Prostate Cancer Patients

New Hyde Park, NY (PRWEB) July 30, 2013

The North Shore-LIJ Health System Department of Radiation Medicine is offering Radium-223 (Xofigo) treatment for men with metastatic prostate cancer that has spread to the bones.

If prostate cancer grows outside of the prostate gland, it spreads into nearby tissues or lymph nodes, and then nearly always spreads to the bones. Spread of cancer to the bones can be painful and result in bone fractures or high blood calcium levels, which can be dangerous or even life threatening. Preventing or slowing the spread of prostate cancer to the bones is a major goal of treatment if the cancer has grown outside of the prostate.

“We have seen remarkable clinical responses in patients who have been treated with Radium-223,” said Brett Cox, MD, chief of brachytherapy in the Department of Radiation Medicine at North Shore-LIJ. “This is a treatment that increases the patients’ life expectancy, improves their chance to have an improved quality of life, and protects the skeleton from serious adverse events associated with prostate cancer spreading to bone. It is an exciting new weapon in the fight against metastatic prostate cancer.”

Radium-223 is an injectible form of radiation which is highly targeted to areas where prostate cancer has spread to bone. Given the unique characteristics of the treatment, the radiation is very focused and precise, only traveling a short distance from the areas containing the prostate cancer spread to bone. This protects the rest of the body from many of the possible damaging effects of treatment.

The North Shore-LIJ Department of Radiation Medicine at Long Island Jewish Medical Center was involved in the pre-clinical trials of the treatment before it was approved by the US Food and Drug Administration (FDA), so the health system has two years’ experience treating patients with Radium-223. In fact, it is one of the first health care providers in the New York metropolitan area to offer treatment with Radium-223.

“Radium-223 is expected to define a new standard of care in the treatment of patients with metastatic prostate cancer and we are excited to be able to offer it as a treatment option to our patients,” noted Louis Potters, MD, chair of radiation medicine.

“After treatment, I am no longer in pain and I’m able to get back to my life,” said Spyros Mantzos of New York, one of Dr. Cox’s patients. “At first, when I heard ‘radiation,’ I was scared, but I am no longer scared of treatment – I have one more round left, I haven’t lost my hair and I feel good.”

In a landmark clinical trial published in the July 18, 2013 issue of the New England Journal of Medicine, treatment with Radium-223 significantly improved the survival of men with metastatic prostate cancer to bone when compared to a placebo treatment. Radium-223 treatment was associated with a 30 percent reduction in the risk of death from prostate cancer as compared to placebo treatments. The treatment was also found to protect the skeleton from complications such as bone fractures, and significantly increases a patient’s chance to have an improved quality of life. Based on these findings and other clinical data, Radium-223 was recently approved by the FDA for use in patients with bone metastases from prostate cancer.

To watch a video about this story, click on the following link: For more information about Radium-223 and/or the Department of Radiation Medicine at Long Island Jewish Medical Center, call (718) 470-7190.

About North Shore-LIJ Health System
One of the nation's largest healthcare systems, North Shore-LIJ delivers world-class clinical care throughout the New York metropolitan area, pioneering research at The Feinstein Institute for Medical Research and a visionary approach to medical education highlighted by the Hofstra North Shore-LIJ School of Medicine. North Shore-LIJ cares for people at every stage of life at 16 hospitals and nearly 400 outpatient physician practices throughout the region. North Shore-LIJ’s owned hospitals and long-term care facilities house more than 6,000 beds, employ more than 10,000 nurses and have affiliations with more than 9,400 physicians. With a workforce of more than 46,000, North Shore-LIJ is the largest employer on Long Island and the third-largest private employer in New York City. For more information, go to

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. iFS Laser Technology at North Shore Eye Care Helping to Set New Standard in LASIK Safety
2. Semi Truck Accident Victims Center Urges Families of a Innocent Victim of a Semi Truck Accident in North Dakota to Call Them for On Their Amazing On The Spot Services
3. A 5-Year-Old North Dakota Girl Overcomes Autism with Use of Skills®, an Online Autism Curriculum
4. North America Food Safety Testing Market to Reach $5,460.1 Million by 2018 at a CAGR of 7.3% - New Report by MarketsandMarkets
5. North Shore-LIJ Health System's Feinstein Institute to Receive $250,000 Grant from Lymphoma Research Foundation Grant to support research of Chronic Lymphocytic Leukemia
6. Keeping Kids Safe: North Shore-LIJ Trains Nassau Police and Youth Explorers in Car Seat Safety
7. Hofstra North Shore-LIJ Medical Scholars Pipeline Program Serves Up a Summer of Enriching Experiences to 61 High School Students
8. Best 2013 Charlotte, North Carolina Security System Companies Rated by
9. Worldwide Power Products Announces Strategic Partnership with Northstar Recovery Services; Attains Registered Vendor Status
10. Hollywood Comes to Thomasville North Carolina’s Favorite Restaurant -Southern Sisters
11. Three North Shore-LIJ Health System Hospitals Called Leaders in LGBT Equality
Post Your Comments:
(Date:11/30/2015)... , ... November 30, 2015 , ... Cycling, running, and ... take on extra meaning the morning of February 28, 2016. , That’s when ... Park and thousands will exercise to help children and families at Joe DiMaggio ...
(Date:11/30/2015)... ... November 30, 2015 , ... A ... of bacteria could be effective in fighting methicillin-resistant Staphylococcus aureus (MRSA), one of ... Their study showed that small molecule analogs that target the functions of SecA, ...
(Date:11/30/2015)... ... November 30, 2015 , ... Using a combination of two blood ... children and adults, according to a new study by researchers at the School of ... Children and Adults: Using Combinations of Blood Glucose Tests ,” published in Frontiers in ...
(Date:11/30/2015)... ... November 30, 2015 , ... International telepathology consultations can ... and KingMed Diagnostics researchers. Their review of more than 1,500 pathology ... pathologists resulted in significantly altered treatment plans for more than half of the ...
(Date:11/30/2015)... PHILADELPHIA (PRWEB) , ... November 30, 2015 , ... ... Philadelphia-based non-profit promoting breast and prostate cancer education and prevention—is joining forces with ... evening of philanthropy and Hollywood elegance on December 7, 2015 at the Union ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... 2015 Cumberland Pharmaceuticals (CPIX), today announced that A.J. ... on December 3, 2015. TIME: 3:15p.m. ET LINK: ... LINK: --> DATE: Thursday, ... --> --> This ... invited to ask the company questions in real-time - both ...
(Date:11/30/2015)... 2015 Varian Medical Systems (NYSE: VAR ) has ... with Apollo Hospitals Group, the largest hospital chain in ... radiation technologists in the country. The MoU was signed by Dr. ... Ashok Kakkar , Varian,s India managing ... India , Varian intends to deploy its Access to Care ...
(Date:11/30/2015)... LONDON and BOSTON , ... to research and develop potential new medicines directed at ... multiple therapeutic areas. --> PFE ) to ... to 10 G protein-coupled receptor (GPCR) targets across multiple ... clinical-stage GPCR structure-guided drug discovery and development company and ...
Breaking Medicine Technology: